PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

Published:2017-08-23 Issue: Volume:8 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Alsaab Hashem O.,Sau Samaresh,Alzhrani Rami,Tatiparti Katyayani,Bhise Ketki,Kashaw Sushil K.,Iyer Arun K.

Funder

National Cancer Institute

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference67 articles.

1. Expression of the PD-1 antigen on the surface of stimulated mouse, T and B lymphocytes;Agata;Int. Immunol.,1996

2. The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis;Aguiar;Immunotherapy,2016

3. Folate decorated nanomicelles loaded with a potent curcumin analogue for targeting retinoblastoma;Alsaab;Pharmaceutics,2017

4. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1B study;Antonia;Lancet Oncol.,2016

5. Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.

Cited by 1342 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Empowering radiotherapy: Harnessing nanomedicines to enhance radiation response and boost antitumor efficacy;Coordination Chemistry Reviews;2024-12

3. Novel therapeutic regimens in previously untreated metastatic urothelial carcinoma: A systematic review and bayesian network meta-analysis;Urologic Oncology: Seminars and Original Investigations;2024-11

4. Intrinsic tumor-targeted murine Ferritin nanocage co-delivers GPX4 and FSP1 inhibitors for synergistic ferroptosis-immunotherapy;Nano Today;2024-10

5. Strategies for engineering oncolytic viruses to enhance cancer immunotherapy;Frontiers in Pharmacology;2024-09-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3